Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06122233

A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease

Led by University of Sydney · Updated on 2025-04-04

400

Participants Needed

4

Research Sites

164 weeks

Total Duration

On this page

Sponsors

U

University of Sydney

Lead Sponsor

M

Monash University

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to compare REBUILD-SM (a purpose-built smartphone app and self-management package) with standard care in people with interstitial lung disease (ILD). The main question it aims to answer is: • Does REBUILD-SM improve health-related quality of life, symptoms, anxiety, self-efficacy and physical activity for people with ILD? Participants in the intervention group will work through the self-management package with support from a healthcare professional via phone or Zoom. They will also enter deidentified health data into the RE-BUILD smartphone app to track their progress over time. Participants in the control group will use a reduced functionality version of the smartphone app only. Researchers will compare both groups to see if there is any difference in health-related quality of life, symptoms, anxiety, self-efficacy and level of physical activity.

CONDITIONS

Official Title

A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of fibrotic interstitial lung disease (ILD)
  • Own a smartphone or tablet and have an email address
  • Able to understand written and spoken English
  • Have adequate digital skills to complete the study requirements
  • On stable ILD treatment for at least 30 days before joining the study
Not Eligible

You will not qualify if you...

  • Do not have a smartphone or tablet
  • Insufficient digital skills to complete the study requirements
  • Unable to communicate in written or spoken English
  • Not on stable ILD treatment for at least 30 days before joining
  • Had an acute exacerbation of ILD within 30 days before joining
  • Currently participating in pulmonary rehabilitation or plan to during the 12-week study period
  • Unable to provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Royal Prince Alfred Hospital

Sydney, New South Wales, Australia, 2050

Actively Recruiting

2

The Prince Charles Hospital

Brisbane, Queensland, Australia, 4032

Actively Recruiting

3

Alfred Hospital

Melbourne, Victoria, Australia, 3004

Actively Recruiting

4

Austin Health

Melbourne, Victoria, Australia, 3084

Actively Recruiting

Loading map...

Research Team

C

Carly Barton

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here